Orbus Therapeutics racks up $32.5 mln Series A

Orbus Therapeutics Inc, a biopharmaceutical company focused on treating rare diseases, has closed $32.5 million in Series A funding. Longitude Capital, H.I.G. BioVentures and Adams Street Partners led the round. Also, the company has named Dr. Ernest Mario, an investor in this current round, as chairman of board.


Calhoun Vision nets $69 mln

Calhoun Vision Inc, a provider of adjustable intraocular lens technology, has raised $69 million in funding. Longitude Capital led the round with participation from H.I.G. BioVentures, Balance Point Capital Partners and RA Capital Management.


NeuWave Medical scores $25 mln Series C

Madison, Wisconsin-based medical device company NeuWave Medical Inc has closed $25 million in Series C financing. Versant Ventures led the round with participation from other investors that included H.I.G. BioVentures and Venture Investors. In conjunction with the funding, NeuWave has added Kirk Nielsen, managing director at Versant Ventures, to its board of directors.


NEA leads $38.9 mln Series B funding in Intact Vascular

New Enterprise Associates led a $38.9 million Series B funding round in Intact Vascular, Inc., which develops medical devices for minimally invasive vascular procedures. Other participants in the funding included Quaker Partners, H.I.G. BioVentures and other existing investors. NEA Partner Justin Klein joined Intact Vascular’s board. Press Release Intact Vascular, Inc., a developer of medical […]

H.I.G. BioVentures leads Series C round for ForSight VISION5

ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5’s board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.

Iconic Therapeutics snags $20 mln

Iconic Therapeutics said Wednesday that it has closed $20 million in Series B-1 financing. The investors were MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures. In conjunction with the funding, Iconic has named MPM partner Dr. William Greene as CEO. Also, MPM’s Todd Foley, H.I.G’s Dr. Bruce Robertson and Dr. Johan Kordel of Lundbeckfond Ventures have been added to Iconic’s board of directors. Based in South San Francisco and Atlanta, Iconic is a biotech firm focused on serious eye disorders.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget